<DOC>
	<DOCNO>NCT02458183</DOCNO>
	<brief_summary>The objective study assess immunogenicity safety DTaP-IPV combination vaccine compare separate DTaP IPV vaccine administer healthy infant 2 , 4 , 6 month age .</brief_summary>
	<brief_title>Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS</brief_title>
	<detailed_description>A multinational , multicenter , randomize , comparative , open-label , phase 3 study Primary Objective : To assess vaccine response rate three-dose primary vaccination Secondary Objectives : To measure antibody titer three-dose primary vaccination ass safety investigational product</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Parent/guardian ( legally authorize representative ) give voluntary write consent subject 's participation fully inform purpose , method , risk , benefit study . Male female infant reach least 7 week age day first dose investigational product . Male female infant identify healthy base physical examination medical history . Subjects acute febrile illness tympanic temperature ≥38.0 ℃ day vaccination . Subjects moderate severe acute disease ( regardless fever ) . Subjects history diphtheria , tetanus , pertussis , poliomyelitis . Subjects major congenital defect . Subjects show evidence continuous hematologic , hepatic , cardiac , renal , respiratory disease . Subjects abnormality immune system , congenital/acquired immune deﬁciency . Subjects received immunosuppressive dose systemic corticosteroid therapy within 30 day vaccination . Subjects likely adverse side effect central nervous system subject ' family history genetic disease central nervous system progressive neurological problem epilepsy . Subjects allergic ingredient investigational product . Subjects receive immunoglobulin blood product plan get medication . Subjects receive vaccine allow protocol plan get prohibit vaccine study period . Subjects currently participate plan participate clinical study study period . Other ineligible condition judge discretion principal investigator subinvestigators .</criteria>
	<gender>All</gender>
	<minimum_age>7 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>